been reported cytologically as non-neoplastic the cytological specimens were reviewed. In one case from the first year of the study a retrospective cytological diagnosis of papillary carcinoma was made, but in all other cases there were no cytological features suggesting neoplasia, although in two cases the specimens would now be classed as unsatisfactory.
Activities of aminotransferases after treatment with streptokinase for acute myocardial infarction Alexander C Maclennan, Naeem Ahmad, James R Lawrence Treatment with streptokinase can increase the serum activities of aspartate aminotransferase and alanine aminotransferase. 2 We examined the activities of aminotransferases in patients who had been treated with streptokinase for acute myocardial infarction to determine the incidence and clinical relevance of this drug reaction.
Subjects, methods, and results
We examined the case records of 189 patients from Dumfries and Galloway Royal Infirmary who had been entered into the second international study of infarction (ISIS 2)-a placebo controlled trial of streptokinase and aspirin in patients who had had a suspected acute myocardial infarction.3 Of our patients, 95 (64 men, 31 women; mean age 58-9 (SD 8 38) years) had received streptokinase and 94 (71 men, 23 women; mean age 56 8 (8-52) years) had received placebo. Venous blood had been taken for assay of enzyme activity on admission to hospital and then once daily for 72 hours.
The figure shows the distribution of the peak activities of aminotransferases as determined from the case records (normal range: aspartate aminotransferase 13 -42 U/I, alanine aminotransferase 11-50 U/l). The geometric mean of the peak activity of aspartate aminotransferase was 157 U/l for patients who received streptokinase and 120 U/I for those who received placebo (p<005; ratio 1-31, 95% confidence interval 1-02 to 11 AUGUST 1990 having increased activity of i-hydroxybutyrate dehydrogenase. Aspartate aminotransferase activities <42 U/I were found in 84 patients who received streptokinase compared with 70 who received placebo. Similarly, alanine aminotransferase activities >50 U/I were found in 48 who received streptokinase compared with 35 who received placebo. Bilirubin concentrations were routinely measured, and increased concentrations were found in 10 of the patients with increased alanine aminotransferase activity who received streptokinase but none of those who received placebo. The activity of y-glutamyltransferase was not routinely measured, but an increased activity (mean 176 U/1; normal range 11-55 U/i) was seen in six patients who received streptokinase who had an increased activity of alanine aminotransferase. Increased A 34 year old woman presented with diarrhoea and increased appetite. Her weight was 60 kg (height 165 cm). She was clinically hyperthyroid with a diffuse goitre. Her serum free thyroxine concentration was 120 pmolIl (normal range 8-8 to 23 pmol/l).
She had developed anorexia nervosa at the age of 18, which had been characterised by abstention from food, self induced vomiting, and amenorrhoea. Her weight had subsequently risen from 42 kg to 55 kg over three months in hospital. Psychiatric support had continued over the next five years. She then maintained a weight of 56 kg over the next 11 years and had normal menstrual periods. She occasionally felt the urge to induce vomiting but refrained from doing so and controlled her weight by dieting. Despite taking carbimazole 45 mg and propranolol 120 mg daily she remained hyperthyroid but refused surgery and treatment with radioactive iodine.
A month after she presented to us her weight rose to 62 kg. She admitted binge eating and vomiting and said that she had lost control over herselfand was frightened of putting on weight. She was clinically hyperthyroid with a heart rate of 140 beats/min. With supervised drug treatment in hospital over two weeks her serum free thyroxine and free triiodothyronine concentrations fell to 11 pmol/l and 7 7 pmol/l respectively. 
Comment
In both these patients hyperthyroidism resulted in weight gain. Hyperthyroidism occasionally causes weight gain by increasing the appetite and hence the intake of energy, which then exceeds the catabolic effect of the disease.2 In case 1 anorexia nervosa was in remission, though the patient's fear of gaining weight persisted. The onset of hyperthyroidism led to the loss of her ability to control her weight by dieting, causing psychological distress. The increase in appetite may have unmasked a long suppressed tendency to bulimia.
